Equity Overview
Price & Market Data
Price: $3.19
Daily Change: +$0.0361 / 1.13%
Daily Range: $3.00 - $3.19
Market Cap: $246,088,816
Daily Volume: 1,334,258
Performance Metrics
1 Week: 6.99%
1 Month: 47.83%
3 Months: 62.77%
6 Months: 94.90%
1 Year: 25.93%
YTD: 70.00%
Company Details
Employees: 213
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.